entertainment -WSS

entertainment

author：comprehensive 2025-09-05 04:57:13 - browse：8

The future looks even brighter for the blockbuster Enhertu, showcased here at ASCO. ADAM FEUERSTEIN/STAT

CHICAGO — The cancer drug Enhertu stalled the growth of tumors by more than a year, significantly longer than standard chemotherapy did in women with the most common form of metastatic breast cancer — a clinical trial result that once again promises to rewrite the rules for the treatment of the disease.

The makers of Enhertu, Daiichi Sankyo and AstraZeneca, said the new data, if cleared by regulators, could shift the way physicians treat hormone receptor-positive, metastatic breast cancer, and create a new standard of care in which patients with breast tumors that express even the faintest amount of HER2 protein can benefit.

“It’s not an overestimation to say that trastuzumab deruxtecan is the most potent drug ever developed for breast cancer,” said Paolo Tarantino, a medical oncologist at the Dana-Farber Cancer Institute, using the scientific name for Enhertu. “It does come with side effects that we’re learning to manage, but with that said, I’ve never seen data like what’s being reported here.”

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Supreme Court strikes down use of affirmative action
Next article： Steward Health Care Massachusetts hospitals face fiscal disaster

hotspot

knowledge

WSS

Shionogi licenses Pompe disease therapy from Maze Therapeutics

Study: Adult vaccinations pay for themselves in societal benefits

Brain worms: The science behind RFK Jr.'s parasitic infection

Telehealth startups turn to complex chronic diseases

First recipient of genetically engineered pig kidney has died

UCLA team creates talking throat patch for voice disorders

explore

entertainment

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

hotspot

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Change Healthcare outage fallout shows need for new oversight

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Readout Newsletter: CAR

The high cost of giving birth even with insurance

Brain worms: The science behind RFK Jr.'s parasitic infection

Hepatitis C has a cure — but many Americans still lack access to it

Steward Health Care Massachusetts hospitals face fiscal disaster

Supreme Court strikes down use of affirmative action

Study: Adult vaccinations pay for themselves in societal benefits

focus

Dairy farmers resist CDC push for PPE against bird flu virus

Researchers on aging grapple with how to calculate biological age

After gene therapy, two congenitally deaf children hear for the first time

Bayer exec: U.S. is key in reviving beleaguered pharma’s drug pipeline

Steward Health Care Massachusetts hospitals face fiscal disaster

Steward Health Care files for bankruptcy

hotspot

hotspot

knowledge

Wikipedia